| Application no. and date | 16837818.0 (espacenet) (Federated) (European Patent Register), 20160818 | | Patent/reg. no. and date | DK/EP 3337502, 20200624 | | Publication date | 20180627 | | Priority no. and date | US 201562207164 P, 20150819 | | EP pub. no. and date |
EP 3337502 20180627 | | Effective date | | | Applicant/owner | AstraZeneca AB,
151 85 Södertälje, SE | | Applicant ref. no. | 1551500 | | Inventor | DEPAZ, Roberto, c/o Medimmune LLC
One Medimmune Way
Gaithersburg, MD 20878, US,
DEJESUS, Natalie, c/o Medimmune LLC
One Medimmune Way
Gaithersburg, MD 20878, US,
BEE, Jared, c/o Medimmune LLC
One Medimmune Way
Gaithersburg, MD 20878, US | | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB, GB | | Opponent | | | IPC Class | A61K 39/00 (2006.01) , A61K 39/395 (2006.01) , C07K 16/00 (2006.01) , C07K 16/18 (2006.01) , C07K 16/28 (2006.01) , C12P 21/00 (2006.01) , C12P 21/08 (2006.01) | | Title | STABIL ANTI-IFNAR1-FORMULERING | | Int. application no. | US2016047506 | | Int. publication no. | WO2017031288 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
